Contact Us » Site Map »
  • About Ambit
    • About Ambit
    • Leadership Team
    • Board of Directors
    • Investors
  • Product Pipeline
    • Product Pipeline
    • Quizartinib (AC220)
    • AC480
    • AC430
    • CEP32496
    • CSF1R Program
    • Kinase Discovery Expertise
    • Publications
  • Clinical Trials
  • Strategic Partnerships
    • Strategic Partnerships
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb (BMS)
    • Cephalon
  • News & Events
    • Press Releases
  • Careers
    • Opportunities
    • Recruiters

Site Map

  •  
  •  
  •  
  •  
Print
About Ambit
  • About Ambit
  • Leadership Team
  • Board of Directors
  • Investors
Product Pipeline
  • Product Pipeline
  • Quizartinib (AC220)
    • Quizartinib in AML
    • Quizartinib in Solid Tumors
  • AC480
    • AC480 Development - Oral Formulation
    • AC480 Development - Intravenous Formulation
  • AC430
  • CEP32496
  • CSF1R Program
  • Kinase Discovery Expertise
    • Scientific Background
    • The Conventional Approach to Kinase Drug Discovery
    • Our Accelerated Approach to Kinase Drug Discovery
  • Publications
    • Peer Reviewed Manuscripts
    • Posters and Presentations
Clinical Trials
Strategic Partnerships
  • Strategic Partnerships
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb (BMS)
  • Cephalon
News & Events
  • Press Releases
Careers
  • Opportunities
  • Recruiters
Privacy Policy » Terms & Conditions » © 2012 Ambit Biosciences Inc.
built@zoomedia